Monoclonal Antibody Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 110 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄

全球單株抗體治療市場在2020年∼2025年間預計將以約13.2%的年複合成長率成長。市場成長的主要原因,是類風濕性關節炎(RA),發炎性腸道疾病,克隆氏症和癌症等的自體免疫疾病的全球擴大的增加,老年人口的增加導致死亡率上升,造成全球負擔。譬如,美國2020年根據American Cancer Society估計,約有180萬6,950的新癌症病例和估計60萬6,520件癌症死亡,對有效率的治療的需求高漲將刺激全球市場成長。



第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 自體免疫疾病的全球盛行率的增加和老年人口的增加
    • US FDA的加速的醫藥品核准舉措和新產品的銷售
  • 阻礙市場要素
    • 心臟衰竭,肝損傷,神經病變,乾癬,許多過敏反應等的併發症的高風險
    • 開發階段的高課題高價的專利產品
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔

  • 各用途
    • 血液疾病
    • 自體免疫疾病
    • 癌症
    • 其他
  • 各來源
    • 人體化
    • 嵌合體
    • 其他
  • 各終端用戶
    • 醫院
    • 民間診所
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • UCB Inc
    • Pfizer Inc
    • Amgen Inc
    • AbbVie Inc
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • Boehringer Ingelheim Pharmaceuticals
    • Novartis International AG
    • Merck kGaA
    • Daiichi Sankyo Company Limited

第7章 市場機會及未來趨勢

Product Code: 67930

The Monoclonal Antibody Therapeutics Market studied was anticipated to grow with a CAGR of nearly 13.2%, during the forecast period. The major factors attributing to the growth of the market are a rise in the global prevalence of autoimmune disorders such as (RA) Rheumatoid Arthritis, Inflammatory Bowel Disorder, Crohn's disease and cancers thus leading to the deaths coupled by the increased geriatric population causing global burden. For instance, according to American Cancer Society estimates for the year 2020 in the U.S., about 1,806,950 new cancer cases and 606,520 cancer deaths were estimated which is projected to be continued in future demanding efficient treatment, likely to fuel the demand for the global market. There are few more factors that play a pivotal role in taking the market to the next level such as approval of blockbuster products in recent years and strong pipeline which is expected to fuel the Monoclonal Antibody Therapeutics across the forecast period.

Key Market Trends

Autoimmune Diseases are Expected to Hold the Largest Market Share in the Monoclonal Antibody Therapeutics Market

  • Autoimmune diseases dominate the market in the forecast period due to the global prevalence of various diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, uveitis, and juvenile idiopathic arthritis. Also, the availability of products such as Humira, a fully human monoclonal antibody approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis fueling the market. On the other hand, the application of these therapeutics in the treatment of cancer is also increasing rapidly along with the rise in approvals and huge investments in the research activities contributing for the highest CAGR of the segment.
  • Based on the end-user, hospitals account for the highest revenue in the market due to increased preference for the patients owing to the prevalence of hospital-associated cases in recent years. Furthermore, the manufacturers of these therapeutics manage to increase the access of their products to as many hospitals and patients as possible to meet their higher requirements fueling the growth of the segment and propelling the global monoclonal antibody therapeutics market revenue in the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall monoclonal antibody therapeutics market throughout the forecast period. The dominance is due to several factors such as rise in geriatric population, increased healthcare expenditure, huge investments by the key players and continuous growth in R&D activities with the rise in application of these therapeutics in the treatment of various disorders such as (PCOS) polycystic ovary syndrome, breast cancers in the United States. For instance, according to the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age and was identified as one of the most common causes of female infertility in the United States fueling the market. Furthermore, the presence of advanced healthcare infrastructure and well-established direct reimbursement policies are also expected to its significant share in the market revenue throughout the forecast period.

Competitive Landscape

The Monoclonal Antibody Therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are acquiring the other companies to consolidate their market positions across the globe and while others are launching new products. For instance, Daiichi Sankyo Company in January 2020 added another blockbuster product, ENHERTU (fam-trastuzumab deruxtecan-nxki), in the U.S. to its existing portfolio of monoclonal antibody therapeutics with the accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2019. which is expected to boost the market furthermore throughout the forecast period. Some of the companies which are currently dominating the market are Abbvie Inc, Daiichi Sankyo Company Limited, Johnson & Johnson, Amgen Inc, and UCB Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of Autoimmune Disorders and Rise in Geriatric Population
    • 4.2.2 New Product Launches with Accelerated Drug Approval Initiative by USFDA
  • 4.3 Market Restraints
    • 4.3.1 High Risk of Complications such as Heart Failure, Liver Injury, Neurological Disorders, Psoriasis and many Allergic Reactions
    • 4.3.2 High Challenges while in the Development Stage and Expensive Patented Products
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Application
    • 5.1.1 Hematological Diseases
    • 5.1.2 Autoimmune Diseases
    • 5.1.3 Cancer
    • 5.1.4 Others
  • 5.2 By Source
    • 5.2.1 Human
    • 5.2.2 Humanized
    • 5.2.3 Chimeric
    • 5.2.4 Others
  • 5.3 By End-user
    • 5.3.1 Hospitals
    • 5.3.2 Private Clinics
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 UCB Inc
    • 6.1.2 Pfizer Inc
    • 6.1.3 Amgen Inc
    • 6.1.4 AbbVie Inc
    • 6.1.5 Johnson & Johnson
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Boehringer Ingelheim Pharmaceuticals
    • 6.1.8 Novartis International AG
    • 6.1.9 Merck kGaA
    • 6.1.10 Daiichi Sankyo Company Limited